Hemophilia A Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030

 Hemophilia A Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030

“Delveinsight Business Research”
DelveInsight’s ‘ Hemophilia A Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hemophilia A epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Hemophilia A is a general term for a group of rare bleeding disorders caused by a congenital deficiency of certain clotting factors. The main form of hemophilia is hemophilia A; it is different from Hemophilia B. The main difference between them is that Hemophilia B is associated with deficiency in factor IX (9) while Hemophilia A is associated with deficiency of factor VIII. More than 80% of people with hemophilia have hemophilia A.


Get FREE sample copy at: 




The DelveInsight  Hemophilia A epidemiology report gives a thorough understanding of the  Hemophilia A by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for  Hemophilia A in the US, Europe, and Japan. The report covers the detailed information of the  Hemophilia A epidemiology scenario in seven major countries (US, EU5, and Japan).


Key Highlights Of The Report

Total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017. .

According to DelveInsight’s analysis, the highest prevalent population of Hemophilia A is in the United States with 14,200 cases in 2017.

Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy.


Hemophilia A Epidemiology

  • Delveinsight’s  Hemophilia A epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. 

  • The  Hemophilia A epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. 

  • The  Hemophilia A epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. 

  • It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

It is observed that severe Hemophilia A cases are far higher in number than mild and moderate cases. It can also be observed that even though mild cases of Hemophilia cases are greater than moderate cases of Hemophilia A, still the combined cases of moderate and severe type of Hemophilia A far outstrips the cases of mild Hemophilia A in 7MM (US, EU5, and Japan)


Scope of the Report

  • The report provides insight into the historical and forecasted patient pool of  Hemophilia A in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of  Hemophilia A.

  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

  • The  Hemophilia A report provides a detailed overview explaining  Hemophilia A causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.

  • The  Hemophilia A Epidemiology Report and Model provide an overview of the risk factors and global trends of  Hemophilia A in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).

  • The report provides the segmentation of the  Hemophilia A epidemiology. 


Key Benefit of  Hemophilia A Epidemiology Report 

The  Hemophilia A Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global  Hemophilia A market

  • Quantify patient populations in the global  Hemophilia A market to improve product design, pricing, and launch plans

  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for  Hemophilia A therapeutics in each of the markets covered

  • Understand the magnitude of  Hemophilia A population by its epidemiology

  • The  Hemophilia A Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources


In the 7MM, approximately 30% of severe hemophilia A cases, i.e., 6,305 patients affected by inhibitors. In addition to this, 70% of the Hemophilia A cases were observed without inhibitors in 2017. The number of cases for both categories will increase during the study period.


Table of Contents

  1. Key Insights 

  2. Executive Summary of  Hemophilia A

  3.  Hemophilia A Disease Background and Overview

  4.  Hemophilia A Patient Journey

  5.  Hemophilia A Epidemiology and Patient Population

  6.  Hemophilia A Treatment Algorithm, Current Treatment, and Medical Practices

  7. KOL Views on  Hemophilia A 

  8.  Hemophilia A Unmet Needs

  9. Appendix

  10. DelveInsight Capabilities

  11. Disclaimer

*The table of contents is not exhaustive; will be provided in the final report


Related Reports

 Hemophilia A Pipeline Insights, 2020

Hemophilia A Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Hemophilia A market.


Hemophilia A Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s “Hemophilia A Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/